重要内容提示： 证券代码：605050 证券简称：福然德 公告编号：2025-054 福然德股份有限公司 关于控股股东、实际控制人的一致行动人 暨持股 5%以上股东减持股份计划的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 控股股东、实际控制人的一致行动人暨持股 5%以上股东持股的基本情况： 本次减持主体为福然德股份有限公司（以下简称"公司"）控股股东、实际控制 人的一致行动人暨持股 5%以上股东宁波人科创业投资合伙企业（有限合伙）（以 下简称"人科合伙"）。截至本公告日，人科合伙持有公司无限售条件流通股 123,750,000 股，占公司总股本的 25.11%，股份来源为公司首次公开发行前取得， 该部分股份已于 2023 年 9 月 25 日解除限售并上市流通。 减持计划的主要内容：公司于 2025 年 12 月 1 日收到人科合伙出具的《关 于减持福然德股份有限公司股份计划的告知函》。因自身资金需求，人科合伙计 划自本公告披露之日起 15 个交易日后的 3 个月内通过集中竞价交易方式及大宗 交易方式减持公 ...

人民财讯12月1日电，福然德（605050）12月1日公告，公司控股股东、实控人的一致行动人暨持股5% 以上股东宁波人科创业投资合伙企业(有限合伙)计划15个交易日后的3个月内，通过集中竞价交易方式 及大宗交易方式，减持公司股份合计不超过1478.49万股，减持比例不超过公司股份总数的3%。 ...

福然德股份有限公司 2025 年第三次临时股东会会议资料 福然德股份有限公司 2025 年第三次临时股东会 会议资料 中国•上海 2025 年 12 月 1 / 7 福然德股份有限公司 2025 年第三次临时股东会会议资料 福然德股份有限公司 2025 年第三次临时股东会会议须知 各位股东： 为维护全体股东的合法权益，确保福然德股份有限公司（以下简称"公司"） 股东会的正常秩序和议事效率，保证大会顺利进行，公司根据《中华人民共和国 公司法》、《上市公司股东会规则》、《公司章程》等有关规定，制定本须知。 一、公司负责本次会议的程序安排和会务工作，出席会议人员应当听从工作 人员安排，共同维护好会议秩序。 二、为保证本次会议的正常秩序，除出席会议的股东及股东代表、董事、监 事、董事会秘书、高级管理人员以及见证律师以外，公司有权拒绝其他人员进入 会场。对于影响本次会议秩序和损害其他股东合法权益的行为，公司将按规定加 以制止。 三、参会股东及股东代理人（以下简称"股东"）须携带身份证明文件及相 关授权文件办理会议登记手续及有关事宜。股东持有效证件完成会议登记后领取 会议资料。 四、参会股东应当按照会议通知时间准时到场， ...

Group 1 - The core point of the article is that Furan De (SH 605050) announced government subsidies totaling 34.655 million yuan, which will significantly impact its financial performance for the year 2024 [1] - The government subsidies include 23.355 million yuan related to income and 11.3 million yuan related to assets, accounting for 10.94% of the company's audited net profit attributable to shareholders for the fiscal year 2024 [1] - For the year 2024, Furan De's revenue composition shows that supply chain services account for 99.93% of total revenue, while other businesses contribute only 0.07% [1] Group 2 - As of the report, Furan De has a market capitalization of 6.6 billion yuan [2]

证券日报网讯 11月24日晚间，福然德发布公告称，2025年1月1日至2025年11月24日，公司收到政府补 助资金3，465.50万元，其中与收益相关的政府补助资金2，335.50万元，与资产相关的政府补助资金1， 130.00万元，占公司2024年度经审计归属于上市公司股东净利润的10.94%。 （文章来源：证券日报） ...

Group 1 - The company, Furan De, announced a profit distribution plan for the mid-term of 2025, proposing a cash dividend of 2.00 yuan (including tax) for every 10 shares to all shareholders [2] - The dividend distribution will be based on the total share capital after deducting the number of shares repurchased and held in the repurchase special account [2] - The announcement was made on the evening of November 24 [2]

Group 1 - Huafeng Co., Ltd. announced a stock suspension due to a potential change in control after signing a share transfer intention agreement [1] - Keshida plans to reduce its shareholding by up to 424,000 shares, representing 0.07% of its total share capital [1] - Jinqilin intends to distribute a cash dividend of 0.10 yuan per share, totaling 19.61 million yuan [1] Group 2 - Rejingshi Biotech has repurchased 904,100 shares, accounting for 0.98% of its total share capital, with a total expenditure of 150 million yuan [2] - Yishitong has repurchased 1,236,500 shares, representing 0.619% of its total share capital, with a total expenditure of approximately 33.49 million yuan [2] Group 3 - Hanjia Design announced the release of a detention on its subsidiary's chairman, allowing him to resume duties [4] - Qingmu Technology plans to acquire 65.83% of Vitalis Pharma AS for 300 million Norwegian Krone (approximately 212 million yuan) [4] - Anda Intelligent's shareholder plans to reduce its stake by up to 2.74% [4] Group 4 - Wansheng Intelligent is a candidate for a project with a pre-bid amount of approximately 42.99 million yuan, representing 4.56% of its audited revenue for 2024 [4] - Yipin Hong received a drug registration certificate for a medication used to treat Alzheimer's symptoms [4] Group 5 - *ST Sansheng received a total of 254 million yuan from restructuring investors [4] - Haichuang Pharmaceutical received approval for clinical trials of HP518 tablets for advanced prostate cancer treatment [4] Group 6 - Ningbo Huaxiang's subsidiary plans to invest 5 million yuan in a venture capital fund focusing on intelligent industries [4] - Petty Co. plans to repurchase shares worth 50 to 70 million yuan [4] Group 7 - Tongji Technology's subsidiary won a construction project with a bid price of 866 million yuan [4] - Prolo Pharmaceutical received a drug registration certificate for a generic drug [4] Group 8 - Jingyan Technology plans to use up to 1.6 billion yuan of idle funds for financial management [4] - Furan De received government subsidies totaling 34.65 million yuan [4] Group 9 - David Medical's subsidiary's medical device registration has been accepted [4] - Jusaylong plans to increase its subsidiary's capital by 170 million yuan through debt-to-equity conversion [4] Group 10 - Heng Rui Pharmaceutical's application for a drug license has been accepted by the National Medical Products Administration [4] - Lege Co. plans to increase its stake in the company by 40 to 80 million yuan [4] Group 11 - New Beiyang's subsidiary won a project with the Bank of Communications [4] - Jiangxi Changyun plans to publicly transfer land use rights and buildings with a starting price of 7.79 million yuan [4] Group 12 - Shenqi Pharmaceutical's subsidiary has paid approximately 16.67 million yuan in tax and penalties [4] - Panjiang Co. plans to invest 1.334 billion yuan in a power plant project [4] Group 13 - Fashilong's vice president resigned for personal reasons [4] - Chunxue Food received government subsidies of 3.79 million yuan [4] Group 14 - China Galaxy completed the repayment of a short-term financing bond totaling 3.025 billion yuan [4] - Jiuzhou Pharmaceutical received approval for a chemical raw material drug [4] Group 15 - Longqi Technology's subsidiary plans to invest 30 million yuan in a venture capital fund [4]

Core Viewpoint - The company Furan De (605050.SH) announced that it received government subsidies totaling 34.655 million yuan from January 1, 2025, to November 24, 2025, which represents 10.94% of the audited net profit attributable to shareholders for the fiscal year 2024 [1] Summary by Category - **Government Subsidies** - The total amount of government subsidies received is 34.655 million yuan [1] - Of this, 23.355 million yuan is related to income, while 11.300 million yuan is related to assets [1] - **Financial Impact** - The government subsidies account for 10.94% of the company's audited net profit attributable to shareholders for the fiscal year 2024 [1]

Core Viewpoint - The company, Furan De (605050.SH), announced a cash dividend distribution of 0.2 yuan per share (tax included) for the first half of 2025, based on the total share capital after accounting for repurchased shares [1] Group 1 - The total share capital of the company is 493 million shares, and after deducting 2.7308 million shares held in the repurchase account, the number of shares eligible for distribution is 490 million [1] - The total cash dividend to be distributed amounts to 9,801.97 million yuan (tax included), which represents 40.27% of the net profit attributable to shareholders of the listed company for the first three quarters of 2025 [1] - The company will not conduct a capital reserve transfer to increase share capital or issue bonus shares during this profit distribution [1]

Core Viewpoint - The company, Furan De (605050.SH), announced a cash dividend distribution of 0.2 yuan per share (tax included) for the first half of 2025, based on the total share capital after accounting for repurchased shares [1] Summary by Relevant Sections - **Dividend Distribution**: The company plans to distribute a cash dividend of 0.2 yuan per share to all shareholders, with a total of 4.90 billion shares eligible for distribution after excluding 2.73 million shares held in the repurchase account [1] - **Total Share Capital**: As of the announcement date, the company's total share capital stands at 493 million shares, and the cash dividend distribution will amount to approximately 9,801.97 million yuan (tax included) [1] - **Profit Allocation**: The proposed cash dividend represents 40.27% of the net profit attributable to shareholders of the listed company for the first three quarters of 2025, with the remaining undistributed profits to be retained [1] - **No Capital Increase**: The company will not conduct a capital reserve transfer to increase share capital or issue bonus shares as part of this profit distribution [1]